Ireland
--:--IST
Recruiting Not applicable

Impact of Daily Stair Climbing on Cardiopulmonary Rehabilitation in Heart Patients

NCT07693348 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Arras
Phase
Not applicable
Started
2026-03-11
Last updated
2026-08-13

Condition(s) studied

Rehabilitation

Investigational drug(s) / intervention(s)

stair climb

stair climb: 2 times a day, until exit service (excluding weekends), they will climb two floors of stairs (morning and afternoon, supervised by a therapist)

Study summary

The goal of this interventional study is to improve exercise capacity of patients following a standard rehabilitation program in Arras Hospital with stair climbing .

Patients will be randomized in to 2 groups : intervention or control.

* Control group will follow standard program.
* Intervention group will follow standard program and stair climbing (2 floors, twice a day until the exit).

Patients will complete questionnaires and tests before starting study and again at the end (approximately 10 days).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years * Patients requiring cardiac rehabilitation admitted to the Eole unit * Patients ability to walk at least 200 meters without technical assistance Exclusion Criteria: * Patient walking with an assistive device * Patient with a contraindication to climbing stairs * Pre-operative patient * Patient with a pacemaker * Patient with an implanted defibrillator

Primary outcome measure(s)

  • Evolution of number of repetitions on chair stand test — at 10 days or at time of study exit if the patient leaves earlier
    Evolution of number of repetitions in 1 minute on chair stand test between entry and exit of study

Trial sites (1)

FacilityCityRegionStatus
Arras general hospital Arras France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07693348 on ClinicalTrials.gov ↗ ← All trials in France